Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$127.77

1.77 (1.40%)

08:22
07/13/18
07/13
08:22
07/13/18
08:22

J&J verdict likely to increase attention on lawsuits, says Credit Suisse

After a Missouri jury on Thursday ordered Johnson & Johnson to pay $4.69B to 22 women who alleged the company's talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer, Credit Suisse analyst Vamil Divan said the large number of ongoing litigations are gaining the attention of investors and is not expected to slow. Given the number of cases related to both talc and mesh and the size of the potential verdicts, Divan says it is "challenging" to put reasonable ranges on what J&J's ultimate liability may end up being, though he notes that J&J has been able to overturn many of the cases and has appealed all of the unfavorable verdicts. Divan maintains an Outperform rating and $151 price target.

  • 17

    Jul

JNJ Johnson & Johnson
$127.77

1.77 (1.40%)

07/06/18
RBCM
07/06/18
NO CHANGE
Target $143
RBCM
Outperform
Johnson & Johnson price target lowered to $143 from $155 at RBC Capital
RBC Capital analyst Glenn Novarro lowered his price target on Johnson & Johnson to $143 ahead of its Q2 results, saying the trends in the U.S. prescription drug market suggest that any upside in the company's Pharmaceutical segment is unlikely. Novarro expects the management to affirm its FY18 guidance for operational growth and earnings, but warns that the revenue guidance may see a downgrade due to the recent USD strength. The analyst also lowered his FY18 revenue projections to $81.1B from $81.3B and FY19 forecast to $80.6B from $83.0B.
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
07/12/18
GSCO
07/12/18
UPGRADE
GSCO
Neutral
Johnson & Johnson upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Jami Rubin upgraded Johnson & Johnson (JNJ) to Neutral with an unchanged price target of $134. The shares closed yesterday down $1.11 to $126.24. The stock is down 10% year-to-date and 15% from its recent all-time high of $148, Rubin tells investors in a research note. She notes J&J is trading in line with the large cap Pharmaceuticals group at 15 times 2019 estimates. The company's non-operational earnings revisions are now better understood by investors at current share levels, Rubin contends. The analyst this morning also downgraded Perrigo (PRGO) to Sell from Neutral.
07/12/18
07/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Neutral from Sell at Goldman Sachs with analyst Jami Rubin saying the stock is down 10% year-to-date and 15% from its recent all-time high of $148. 2. Hallmark Financial (HALL) upgraded to Outperform from Market Perform at Raymond James. 3. Transocean (RIG), Ensco (ESV), and Rowan Companies (RDC) were upgraded to Buy from Hold at Tudor Pickering. 4. Precision Drilling (PDS) and Nabors Industries (NBR) were upgraded to Overweight from Equal Weight at Morgan Stanley. 5. CA Technologies (CA) upgraded to Market Perform from Underperform at Wells Fargo and Bernstein. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

BA

Boeing

$356.01

5.2 (1.48%)

07:22
07/17/18
07/17
07:22
07/17/18
07:22
Hot Stocks
Boeing signs integrated services agreement with Blackshape »

Boeing announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

NFLX

Netflix

$400.24

4.32 (1.09%)

07:22
07/17/18
07/17
07:22
07/17/18
07:22
Recommendations
Netflix analyst commentary  »

Oppenheimer remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$400.24

4.32 (1.09%)

07:22
07/17/18
07/17
07:22
07/17/18
07:22
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INXN

Interxion

$64.05

0.77 (1.22%)

07:21
07/17/18
07/17
07:21
07/17/18
07:21
Initiation
Interxion initiated  »

Interxion resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

07:20
07/17/18
07/17
07:20
07/17/18
07:20
General news
FX Update: The Dollar remained on a softening tack »

FX Update: The Dollar…

BAESY

BAE Systems

$0.00

(0.00%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Periodicals
BAE Systems wants international partners for UK fighter project, Reuters says »

BAE Systems wants to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INAP

Internap

$11.31

-0.63 (-5.28%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Initiation
Internap initiated  »

Internap resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$138.45

-0.91 (-0.65%)

, MA

MasterCard

$204.05

-1.86 (-0.90%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Recommendations
Visa, MasterCard analyst commentary  »

Visa price target raised…

V

Visa

$138.45

-0.91 (-0.65%)

MA

MasterCard

$204.05

-1.86 (-0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

FDC

First Data

$22.24

-0.06 (-0.27%)

07:19
07/17/18
07/17
07:19
07/17/18
07:19
Recommendations
First Data analyst commentary  »

First Data price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

EQIX

Equinix

07:17
07/17/18
07/17
07:17
07/17/18
07:17
Initiation
Equinix initiated  »

Equinix resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Aug

MA

MasterCard

$204.05

-1.86 (-0.90%)

07:17
07/17/18
07/17
07:17
07/17/18
07:17
Recommendations
MasterCard analyst commentary  »

MasterCard price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

AUTL

Autolus Therapeutics

$23.00

2.11 (10.10%)

07:16
07/17/18
07/17
07:16
07/17/18
07:16
Initiation
Autolus Therapeutics initiated  »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVT

Avnet

07:15
07/17/18
07/17
07:15
07/17/18
07:15
Initiation
Avnet initiated  »

Avnet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARW

Arrow Electronics

$77.09

-0.47 (-0.61%)

07:15
07/17/18
07/17
07:15
07/17/18
07:15
Initiation
Arrow Electronics initiated  »

Arrow Electronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QURE

uniQure

$35.08

-4.41 (-11.17%)

, PFE

Pfizer

$37.39

-0.14 (-0.37%)

07:15
07/17/18
07/17
07:15
07/17/18
07:15
Recommendations
uniQure, Pfizer analyst commentary  »

uniQure pullback on…

QURE

uniQure

$35.08

-4.41 (-11.17%)

PFE

Pfizer

$37.39

-0.14 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

AMBA

Ambarella

$37.58

-0.32 (-0.84%)

07:14
07/17/18
07/17
07:14
07/17/18
07:14
Initiation
Ambarella initiated  »

Ambarella initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BF.B

Brown-Forman, also tag with BFA, BFB

$51.18

0.14 (0.27%)

, BFA

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

07:13
07/17/18
07/17
07:13
07/17/18
07:13
Upgrade
Brown-Forman, also tag with BFA, BFB, Brown-Forman, also tag with BF.A, BF.B, Brown-Forman, also tag with BF.A, BF.B rating change  »

Brown-Forman upgraded to…

BF.B

Brown-Forman, also tag with BFA, BFB

$51.18

0.14 (0.27%)

BFA

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

BFB

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$207.33

(0.00%)

07:13
07/17/18
07/17
07:13
07/17/18
07:13
Periodicals
Facebook uses 'shielded review' process for popular pages, The Guardian reports »

Leading far-right…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 25

    Jul

  • 18

    Sep

CHUY

Chuy's

07:11
07/17/18
07/17
07:11
07/17/18
07:11
Downgrade
Chuy's rating change  »

Chuy's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

DLR

Digital Realty

$115.64

-0.66 (-0.57%)

07:11
07/17/18
07/17
07:11
07/17/18
07:11
Initiation
Digital Realty initiated  »

Digital Realty resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

NFLX

Netflix

$400.24

4.32 (1.09%)

07:10
07/17/18
07/17
07:10
07/17/18
07:10
Recommendations
Netflix analyst commentary  »

Netflix valuation remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLMN

Bloomin' Brands

$20.72

-0.36 (-1.71%)

07:09
07/17/18
07/17
07:09
07/17/18
07:09
Upgrade
Bloomin' Brands rating change  »

Bloomin' Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

CANF

Can-Fite BioPharma

$1.23

-0.04 (-3.15%)

07:09
07/17/18
07/17
07:09
07/17/18
07:09
Hot Stocks
Can-Fite BioPharma receives patent from China, Australia for sexual dysfunction »

Can-Fite BioPharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COR

CoreSite Realty

$112.91

-0.86 (-0.76%)

07:09
07/17/18
07/17
07:09
07/17/18
07:09
Initiation
CoreSite Realty initiated  »

CoreSite Realty resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

INNT

Innovate Biopharmaceuticals

$8.07

-15.65 (-65.98%)

07:08
07/17/18
07/17
07:08
07/17/18
07:08
Initiation
Innovate Biopharmaceuticals initiated  »

Innovate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.